News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Seyed Alireza Javadinia: Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous SCC
Seyed Alireza Javadinia/LinkedIn
Apr 6, 2025, 10:38

Seyed Alireza Javadinia: Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous SCC

Seyed Alireza Javadinia, Clinical Oncologist at Sabzevar University of Medical Sciences, shared an article by Paolo Bossi, et al. on LinkedIn:

“The I-TACKLE trial by Paolo Bossi; Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous SCC:

Median treatment durations were 3 months (pembrolizumab) and 4 months (combination).

Highlights:

1. Cetuximab overcame pembrolizumab resistance, reaching a 63 % cumulative ORR.
2. Cetuximab reversed primary/acquired resistance in 43 % of cSCC cases, with safety.”

Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial.

Authors: Paolo Bossi, et al.

Seyed Alireza Javadinia: Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous SCC

cancer cetuximab fight against cancer Global fight against cancer I-TACKLE trial immunotherapy metastatic cutaneous SCC OncoDaily Oncology Paolo Bossi pembrolizumab Sabzevar University of Medical Sciences Seyed Alireza Javadinia
Special Coverage
Science
Apr 6, 2025, 10:38
Seyed Alireza Javadinia: Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous SCC
Blog
Apr 6, 2025, 10:28
Rawia Mohamed: Integrating Morphology and Molecular Profiling
Blog
Apr 6, 2025, 10:25
Teresa Amaral: Great organization and science at the 11th World Melanoma Congress in Athens
Blog
Apr 6, 2025, 10:18
Wafaa M Rashed: Join the Global Conversation on Cancer Predisposition in Children
Blog
Apr 6, 2025, 10:10
Razelle Kurzrock: Lessons learned from a decade of immune checkpoint inhibition
Blog
Apr 6, 2025, 10:07
Polikalipo Kagina: Surrounded by transparent images of radiotherapy machines and smiling faces of cancer survivors
Science
Apr 6, 2025, 09:58
Rasha Aboelhassan: Great success comes only when you share your experience with others
Blog
Apr 6, 2025, 09:50
Arjun K Ghosh: Great experience to interact with cardio-oncology leaders from Egypt
Blog
Apr 6, 2025, 09:37
Catherine Alix-Panabières: Circulating Tumor Cells module of the Universitary Diploma "LIQUID BIOPSY"
Science
Apr 6, 2025, 09:36
Myeloma Paper of the Day, April 6th, suggested by Robert Orlowski
Blog
Apr 6, 2025, 09:29
Successfully concluded the second workshop of the APAC Lung Cancer Policy Consensus initiative - ASPIRE for Lung Cancer
Science
Apr 6, 2025, 09:16
M. Bilal Abid: Outcomes of NDMM patients who undergo autoHCT after achieving suboptimal response to induction